President Donald Trump on Wednesday nominated Dr. Heidi Overton, a physician and deputy assistant to the president for domestic policy, to serve as commissioner of the U.S. Food and Drug Administration (FDA). The announcement, made via a post on Truth Social, follows months of leadership turnover at the agency, which has faced internal debates over policies such as flavored e-cigarettes and access to abortion medications.
Overton, who holds a medical degree from the University of New Mexico and completed a general surgery residency at Johns Hopkins University School of Medicine, would replace former commissioner Dr. Marty Makary, who resigned in May amid tensions with the White House over vaping policy and abortion pill regulations. The FDA has been operating under an acting commissioner, Kyle Diamantas, since Makary’s departure.
Senate confirmation required
Overton’s nomination must be confirmed by the U.S. Senate before she can assume the role. If confirmed, she would oversee an agency currently addressing a multistate cyclospora outbreak linked to food safety concerns.
Background and Prior Roles
Overton previously served as a White House fellow during Trump’s first term and later led health policy at the America First Policy Institute from 2021 to 2025. She has been a close collaborator with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services head Dr. Mehmet Oz, both of whom have been central to the administration’s health policy agenda.
In a Truth Social post, Trump described Overton as a “ROCKSTAR” in his administration and emphasized her role in advancing priorities such as faster cures, lower drug prices, and clinical trial reforms. He also highlighted her involvement in the recent executive order revising childhood vaccine recommendations, which she attended in the Oval Office.
Policy Positions and Advocacy
Overton is widely known for her pro-life views, a stance that has drawn praise from anti-abortion advocacy groups. Organizations such as Live Action and Americans United for Life have publicly endorsed her nomination, framing it as an opportunity to restrict access to abortion medications—particularly mifepristone—by reinstating in-person screening requirements for dispensing the drug. Overton participated in the 2025 March for Life rally alongside Vice President JD Vance.
Critics of the nomination argue that Overton’s policy positions could undermine FDA independence and limit access to reproductive health services. The agency has faced prior scrutiny over decisions related to abortion pill regulations, with former commissioner Makary clashing with the White House over the issue.
Agency Challenges Ahead
The FDA’s next commissioner will inherit a range of pressing issues, including:
- Food safety concerns following the recent cyclospora outbreak.
- Regulatory debates over vaping products and flavored e-cigarettes.
- Reproductive health policies, particularly regarding the abortion pill mifepristone.
- Drug pricing and innovation, central to the administration’s “Make America Healthy Again” agenda.
Overton’s confirmation process is expected to draw significant attention, with senators likely to question her stance on these and other FDA-related issues.